Tag: IP

American BioDefense Institute Forum w/ Executive Director Dr. Ravi Starzl & Jeff Pegues CBS News

Learn about Passive Immunity and a new model for public health during pandemics with media, sports, political and science community leaders.

Join CBS News Homeland Security Correspondent Jeff Pegues, Congressman Paul Gosar, The New Orleans Saints all-time leading wide receiver Marques Colston, Executive Director of American BioDefense Institute Dr. Ravi Starzl, Attorney and Veteran advocate John Berry, and IP strategist JiNan Glasgow George for a one of a kind forum hosted by The American BioDefense Institute.

Five months ago our health system was caught flat-footed. We’ve seen an unprecedented impact on society. In the U.S. alone we’ve seen over 150,000 deaths, unprecedented unemployment, and seen major interruptions in many aspects of American life including business, law, and sports.

The Vaccine Race Continues: Novavax Looks to Make Strides

As part of our ongoing look at how American companies are stepping up to confront the virus, we have news from Novavax brought to you by JiNan Glasgow George.

By securing a US federal grant of $1.6 billion for the development of 100 million doses of COVID-19 vaccine, Novavax has joined the ranks of top COVID-19 vaccine producers in America. This recent deal marks the $4 billion investment milestone for vaccine development through public-private partnerships, also known as “Operation Warp Speed.” Moderna is another well-known American vaccine manufacturer that has secured over $500 million in federal grants. Notably, Magic Number’s Patent Radian® data covering the Pandemics/Epidemics technology sector shows Novavax & Moderna as the top two patent owners in this space. This data confirms the significant investment in research & development and patent assets by both companies – a hallmark of successful pharmaceutical and biotechnology commercial success..

CureVac AG, a German biopharmaceutical company, rounds out the top 3 patent owners in this list; CureVac has secured funding of $338 million from the federal government of Germany. CureVac and Moderna are pioneers in the mRNA vaccine market, while Novavax has introduced a novel approach of combining a proprietary adjuvant with a recombinant nanoparticle vaccine. The US government’s Operation Warp Speed investing a major share of its resources in Novavax may be a good bet, since the company has realized success in its Phase 1 trials and appears to have a solid foundation of patent assets. There is momentum here, and great expectation that Novavax will be producing an effective and safe vaccine by the end of 2020.

You can learn more about US patent assets owned by Novavax, Moderna, and Curevac for the last 2.5 years. Here Magic Number’s Pandemic Patent Forecast®.

 

JiNan Glasgow George
Contributor American BioDefense Institute
CEO Magic Number